Head­ed for a block­buster smash, Roche picks up an­oth­er key OK for land­mark MS drug Ocre­vus

Roche’s quest to make its pi­o­neer­ing MS drug Ocre­vus in­to a multi­bil­lion-dol­lar block­buster has gath­ered some added steam with an EU mar­ket­ing ap­proval — 9 months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER